Rare disease news, mapped to the diseases behind the headlines. AI-classified across pipeline, policy, funding, science, and community.
Be among the first to receive Kisho Intelligence Briefings
Showing news related to
Showing 1–1 of 1 stories
Real-world data confirms that inotuzumab ozogamicin significantly improves remission rates in relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL), with a 51.7% overall survival rate. The study highlights a 71.4% MRD-negative status in patients, facilitating further treatment options like ASCT or CAR T.
Read full storyGet the week's most important rare disease developments — pipeline moves, policy changes, and funding signals — delivered to your inbox every Monday.
Free weekly briefing. Unsubscribe anytime.